Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - LA JOLLA PHARMACEUTICAL CO | exhibit321fy201910-k.htm |
| EX-31.1 - EXHIBIT 31.1 - LA JOLLA PHARMACEUTICAL CO | exhibit311fy201910-k.htm |
| EX-21.1 - EXHIBIT 21.1 - LA JOLLA PHARMACEUTICAL CO | exhibit211fy2019.htm |
| EX-10.5 - EXHIBIT 10.5 - LA JOLLA PHARMACEUTICAL CO | exhibit105fy201910-k.htm |
| EX-10.1 - EXHIBIT 10.1 - LA JOLLA PHARMACEUTICAL CO | exhibit101fy201910-k.htm |
| EX-4.2 - EXHIBIT 4.2 - LA JOLLA PHARMACEUTICAL CO | exhibit42fy201910-k.htm |
| 10-K - 10-K - LA JOLLA PHARMACEUTICAL CO | ljpc-201910xk.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
La Jolla Pharmaceutical Company
San Diego, CA
We consent to the incorporation by reference in Registration Statements (No. 333-214721), (No. 333-221198) and (333-227818) on Form S-3 and (No. 333-184909), (No. 333-193016), (No. 333-207212), (No. 333-214722), (No.333-221197) and (No. 333-227819) on Form S-8 of La Jolla Pharmaceutical Company of our reports dated March 2, 2020, relating to the consolidated financial statements and effectiveness of internal control over financial reporting of La Jolla Pharmaceutical appearing in this Annual Report on Form 10-K of La Jolla Pharmaceutical Company for the year ended December 31, 2019.
/s/ SQUAR MILNER LLP
March 2, 2020
San Diego, California